Abstract:Objectives: Glutathione S-transferase (GST) isoenzymes play important roles in resistance to cell apoptosis and carcinogenesis. We aimed to establish the relationship between GST expression and the prognosis of upper urinary tract urothelial carcinoma (UTT-UC) in Taiwan. Methods: This study retrospectively reviewed 46 patients with pathologically confirmed UUT-UC at Kaohsiung Medical University Hospital. In each patient, expression of GSTT1 and GSTP1 was compared between urothelial carcinoma and normal urothel… Show more
“…In comparison to our findings, several studies have reported an upregulated GSTP1 expression which increased gradually with high-grade tumor or invasive-stage and was linked to decreased levels of urothelial cells apoptosis (Chen et al, 2013;Pljesa-Ercegovac et al, 2011;Savic-Radojevic et al, 2007).…”
Section: )contrasting
confidence: 71%
“…Some studies indicated an overexpression of GSTP1 gene in esophageal cancer (Joshi et al., ), colorectal cancer (Zhang et al., ), renal cancer (Kaprilian et al., ), lung cancer (Yang et al., ), and in BC (Chen et al., ; Pljesa‐Ercegovac et al., ; Savic‐Radojevic et al., ). Other studies showed reduced GSTP1 gene expression in prostate, endometrial, hepatocellular, and ovarian cancers (Chan et al., ; Li et al., ; Lin et al., ; Martignano et al., ; Mian et al., ; Shilpa et al., ; Zelic et al., ; Zhang et al., ).…”
Section: Discussionmentioning
confidence: 99%
“…, lung cancer (Yang et al, 2006), and in BC (Chen et al, 2013;Pljesa-Ercegovac et al, 2011;Savic-Radojevic et al, 2007). Other studies showed reduced GSTP1 gene expression in prostate, endometrial, hepatocellular, and ovarian cancers (Chan et al, 2005;Li et al, 2015;Lin et al, 2001;Martignano et al, 2016;Mian et al, 2016;Shilpa et al, 2014;Zelic et al, 2016;Zhang et al, 2015).…”
BackgroundGlutathione S‐transferase pi 1 (GSTP1) is a cytosolic detoxifying enzyme that protects cells against deleterious effects of oxidative stress. Deregulated expression of GSTP1 protein and aberrant promoter methylation of GSTP1 gene were reported in various human tumors and were shown to be involved in the molecular pathway for cancer development.Aims and methodsIn this study, we aimed to determine the expression status of GSTP1 in relation to its gene promoter methylation in Moroccan population of 30 bladder cancer (BC) patients and in two noncancerous bladder tissues used as controls. GSTP1 expression was assessed by immunohistochemistry and GSTP1 gene promoter methylation status was studied by methylation‐specific PCR (MS‐PCR).ResultsGlutathione S‐transferase pi 1 was expressed in the two normal tissues. In BC cases, GSTP1 expression was strong in 23.33% (7/30), moderate in 60% (18/30), and weak in 13.33% (4/30) of cases, while GSTP1 was not expressed in one cancer case (3.33%). Variability of GSTP1 expression does not correlate with high‐grade cancer or invasive‐stage (p > 0.05). No GSTP1 gene promoter methylation was detected in all control and cancer cases.ConclusionOur data suggest that GSTP1 expression is not associated with BC development, limiting its use as a biomarker for BC management in Morocco. Moreover, difference in GSTP1 expression among BC cases is not due to GSTP1 promoter methylation.
“…In comparison to our findings, several studies have reported an upregulated GSTP1 expression which increased gradually with high-grade tumor or invasive-stage and was linked to decreased levels of urothelial cells apoptosis (Chen et al, 2013;Pljesa-Ercegovac et al, 2011;Savic-Radojevic et al, 2007).…”
Section: )contrasting
confidence: 71%
“…Some studies indicated an overexpression of GSTP1 gene in esophageal cancer (Joshi et al., ), colorectal cancer (Zhang et al., ), renal cancer (Kaprilian et al., ), lung cancer (Yang et al., ), and in BC (Chen et al., ; Pljesa‐Ercegovac et al., ; Savic‐Radojevic et al., ). Other studies showed reduced GSTP1 gene expression in prostate, endometrial, hepatocellular, and ovarian cancers (Chan et al., ; Li et al., ; Lin et al., ; Martignano et al., ; Mian et al., ; Shilpa et al., ; Zelic et al., ; Zhang et al., ).…”
Section: Discussionmentioning
confidence: 99%
“…, lung cancer (Yang et al, 2006), and in BC (Chen et al, 2013;Pljesa-Ercegovac et al, 2011;Savic-Radojevic et al, 2007). Other studies showed reduced GSTP1 gene expression in prostate, endometrial, hepatocellular, and ovarian cancers (Chan et al, 2005;Li et al, 2015;Lin et al, 2001;Martignano et al, 2016;Mian et al, 2016;Shilpa et al, 2014;Zelic et al, 2016;Zhang et al, 2015).…”
BackgroundGlutathione S‐transferase pi 1 (GSTP1) is a cytosolic detoxifying enzyme that protects cells against deleterious effects of oxidative stress. Deregulated expression of GSTP1 protein and aberrant promoter methylation of GSTP1 gene were reported in various human tumors and were shown to be involved in the molecular pathway for cancer development.Aims and methodsIn this study, we aimed to determine the expression status of GSTP1 in relation to its gene promoter methylation in Moroccan population of 30 bladder cancer (BC) patients and in two noncancerous bladder tissues used as controls. GSTP1 expression was assessed by immunohistochemistry and GSTP1 gene promoter methylation status was studied by methylation‐specific PCR (MS‐PCR).ResultsGlutathione S‐transferase pi 1 was expressed in the two normal tissues. In BC cases, GSTP1 expression was strong in 23.33% (7/30), moderate in 60% (18/30), and weak in 13.33% (4/30) of cases, while GSTP1 was not expressed in one cancer case (3.33%). Variability of GSTP1 expression does not correlate with high‐grade cancer or invasive‐stage (p > 0.05). No GSTP1 gene promoter methylation was detected in all control and cancer cases.ConclusionOur data suggest that GSTP1 expression is not associated with BC development, limiting its use as a biomarker for BC management in Morocco. Moreover, difference in GSTP1 expression among BC cases is not due to GSTP1 promoter methylation.
“…Upper urinary tract urothelial carcinoma (UTUC) comprises only 5% of all urothelial tumors in Western countries [1], but its incidence is high in Taiwan, with a ratio 3.08:6.72, UTUC to urinary bladder urothelial carcinoma (UBUC) [2]. Despite advances in surgical technique and improved understanding of UC carcinogenesis [3–7], 5-year survival rates for patients remain suboptimal [8, 9].…”
Urothelial carcinoma (UC) occurs in the upper urinary tract (UTUC) and the urinary bladder (UBUC). The molecular pathogenesis of UC has not been fully elucidated. Through data mining of a published transcriptome of UBUC (GSE31684), we identified Minichromosome Maintenance Complex Component 2 (MCM2) and MCM10 as the two most significantly upregulated genes in UC progression among the MCM gene family, the key factors for the initiation of DNA replication. To validate the clinical significance of MCM2 and MCM10, immunohistochemistry, evaluated by H-score, was used in a pilot study of 50 UTUC and 50 UBUC samples. Only a high expression level of MCM10 predicted worse disease-specific survival (DSS) and inferior metastasis-free survival (MeFS) for both UTUC and UBUC. Correspondingly, evaluation of MCM10 mRNA expression in 36 UTUCs and 30 UBUCs showed significantly upregulated levels in high stage UC, suggesting its role in tumor progression. Evaluation of 340 UTUC and 296 UBUC tissue samples, respectively, demonstrated that high MCM10 immunoexpression was significantly associated with advanced primary tumors, nodal status, and the presence of vascular invasion in both groups of UCs. In multivariate Cox regression analyses, adjusted for standard clinicopathological features, MCM10 overexpression was independently associated with DSS (UTUC hazard ratio [HR]=2.401, P = 0.013; UBUC HR=4.323, P=0.001) and with MeFS (UTUC HR=3.294, P<0.001; UBUC HR=1.972, P=0.015). In vitro, knockdown of MCM10 gene significantly suppressed cell proliferation in both J82 and TCCSUP cells. In conclusion, MCM10 overexpression was associated with unfavorable clinicopathological characteristics and independent negative prognostic effects, justifying its potential theranostic value in UC.
“…In addition, deregulated GSTT1 expression has been observed in some cancers including bladder cancer, breast cancer and glioma (Dialyna et al, 2001;Diedrich et al, 2006;Ha et al, 2011;Chen et al, 2013). A previous study comparing GSTT1 protein levels in paired normal tissue and colorectal and gastric tumors has found a mild decrease in GSTT1 protein levels (de Bruin et al, 1999).…”
Our aim was to determine GSTT1 expression levels in left colon tumors and paired normal tissue in order to identify specific alterations in GSTT1 mRNA levels. Alterations in GSTT1 expression in twenty-four leftsided colon tumors and paired cancer free tissue were determined by qRT-PCR. Significant fold changes were determined with t-test. When compared with cancer free tissue, left colon cancers showed a significant decrease in GSTT1 expression. However, GSTT1 mRNA levels among different grades increased gradually in correlation with tumor grade. Our results suggest that downregulation of GSTT1 in left-sided colon cancers is an early event and is reversed with cancer progression, probably due to cellular defense mechanisms as a response to changes in the microenvironment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.